Rubella Susceptibility Predicts Measles Susceptibility : Implications for Postpartum Immunization

1. Tadros TS, Workowoski KA, Siegel RJ, Hunter SH; Schwartz DA. Pathology of Hyalohyphomycosis caused by Scedosporium apiospermum (Pseudoallescheria boydii): an emerging mycosis. Hum Pathol 1998;29:1266–72. 2. Walsh TJ, Peter J, McGough DA, Fothergill AW, Rinaldi MG, Pizzo PA. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudoallescheria boydii. Antimicrob Agents Chemother 1995;39:1361–64. 3. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998;42:741–5. 4. Espinell-Ingroff A. In vitro activity of the new triazole voriconazole (UK109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998;36:198–202. 5. Denning D, Del Favero A, Gluckman E, Norfolk, D, Ruhnke M, Yonren S, Troke P, Sarantis, N. UK-109,496, a novel , wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis [abstract F80]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:126. 6. Dupont B, Denning D, Lode H, Yonren P, Troke, P, Sarantis, N. UK-109,496, a novel , wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. 1995. [abstract F81]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:127. 7. Girmenia C, Luzi, G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 1998;36:1436–8. 8. Jabado N, Casanova JL, Haddad E, Dulieu F, Fournet JC, Dupont B, Fisher A, Hennequin C, Blanche S. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 1998;27:1437–41. 9. Torok L, Simon G, Csornal A, Tapai M, Torok I. Scedosporium apiospermum infection imitating lymphocutaneous sporotrichosis in a patient with myeloblastic-monocytic leukemia Br J Dermatol 1995;133:805–9. 10. Ichikawa T, Saiki M, Tokunaga S, Saida T. Scedosporium apiospermum skin infection in a patient with nefrotic syndrome. Acta Derm Venereol 1997;77:172–3. 11. Lemerle E, Bastien M. , Demolliens-Dreus, G, Forest JL, Boyer E, Chabasse D, Celerier P. Scedosporiose cutanee revelee par un purpura bullo-necrotique. Ann Dermatol Venereol 1998;125:711–4. 12. Miyamoto T, Sasaoka R, Kawaguchi M, Ishioka S, Inoue T, Yamada N, Mihara M. Scedosporium apiospermum skin infection: a case report an review of the literature. J Am Acad Dermatol 1998;39:498–500. 13. Nomdedeu J, Brunet S, Martino R, Altes A, Ausina V, Domingo-Albos A. Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: case report. Clin Infect Dis 1993;16:731–3. 14. Goldberg SL, Geha DJ, Marshall WF, Inwards DJ, Hoagland HC. Successful treatment of simultaneous pulmonary Pseudoallescheria boydii and Aspergillus terreus infection with oral itraconazole. Clin Infect Dis 1993;16: 803–5. 15. Pfaller MA, Bartlett MS, Espinel-Ingroff A, et al. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi: proposed standard (1998). National Committee for Laboratory Standards, 1998. Document M38-P, vol 18, no. 13.